On 30th April 2025, the MHRA approved the use of a new under the skin injection version (subcutaneous) of Nivolumab on 30th April 2025.

The subcutaneous formulation of nivolumab can be given as a 3–5-minute injection instead of the 30- or 60-minute intravenous (IV) infusion. This will allow up- to 1000 hours per month of treatment time to be freed up relieving the pressure on stretched cancer day units and aseptic units.

Bath ASU are keen to support the NHS in the switch to nivolumab SC and are actively looking to contribute to increasing patient safety with injectable medicines and freeing up nursing capacity in the NHS.

With these aims in mind, we are pleased to announce that we will be offering Nivolumab SC as a compounded product with an extended shelf life compared to the SPC.

For further details on this please contact your account manager.

If you have any questions about this change, please complete the form below and one of our team will respond.